Branded

FDA approves Parkinson’s drug
WASHINGTON — The U.S. Food and Drug Administration on Tuesday approved Newron Pharmaceuticals’ Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. An “off” episode is a time when a patient’s medications are not working well, causing an increase in Parkinson’s symptoms, such as tremor and difficulty walking.
Analysis: Entresto improves glycemic control
EAST HANOVER, N.J. — A post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggest that Entresto (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril.

Report: CVS Health says new Amgen data could expand Repatha eligibility
Adapt Pharma highlights naloxone nasal spray efficacy at AAPM

ORLANDO, Fla. — A little more than a year after its approval, Adapt Pharma made the case for the effectiveness of its Narcan (naoloxone) Nasal Spray 4 mg at the annual American Academy of Pain Medicine, here, on Thursday with real-world use data. The survey collected case data and outcomes of opioid overdose reversal attempts by first responders and community health organizations using the nasal spray.
Report: 5 takeaways from the CBO’s analysis of AHCA
Report: New data highlights imatinib’s efficacy
Genentech, Publix, Mars and Regeneron named to Fortune’s 100 Best Companies to Work For list

NEW YORK — Genentech, Publix, Mars and Regeneron Pharmaceuticals were named to Fortune magazine’s 100 Best Companies to Work For list. The listings are based upon reviews by company employees.
CVS to dispense naloxone prescription-free in four more states

WOONSOCKET, R.I. — CVS Pharmacy added Arizona, Georgia, Iowa and South Carolina to the list of stated where it now dispenses the opioid overdoes reversal drug naloxone to patients without a prescription. CVS Pharmacy locations in 41 states are now able to increase access to this medication.
FDA approves Noctiva

WASHINGTON — The U.S. Food and Drug Administration approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night). Noctiva is the first FDA-approved treatment for this condition.

Noctiva is marketed by Renaissance Lakewood for Serenity Pharmaceuticals.
NCPA endorses latest prescription transparency legislation

WASHINGTON — Reps. Doug Collins, R-Ga., and Dave Loebsack, D-Iowa, on Thursday introduced H.R. 1316, the Prescription Drug Price Transparency Act, to protect taxpayers and the community pharmacists who serve them by requiring greater transparency from pharmacy benefit managers.

FDA approves Parkinson’s drug

Analysis: Entresto improves glycemic control

Report: CVS Health says new Amgen data could expand Repatha eligibility

Adapt Pharma highlights naloxone nasal spray efficacy at AAPM

Report: 5 takeaways from the CBO’s analysis of AHCA

Report: New data highlights imatinib’s efficacy

Genentech, Publix, Mars and Regeneron named to Fortune’s 100 Best Companies to Work For list

CVS to dispense naloxone prescription-free in four more states

FDA approves Noctiva

NCPA endorses latest prescription transparency legislation